Ophthalmology – Page 3

Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients

By MedXY 08/17/2025

A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.

Clinical Updates news Ophthalmology Specialties

Decoding the Blink: How Segmental Control of the Orbicularis Oculi Could Enable Blink Neuroprostheses

By MedXY 08/09/2025

UCLA engineers and ophthalmologists mapped segmental, task-dependent activation of the orbicularis oculi during five closure behaviors, defining a roadmap for targeted neurostimulation to restore protective blinking in patients with eyelid paralysis.

Clinical Updates news Ophthalmology Specialties

Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief

By MedXY 08/02/2025

Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.

Clinical Updates news Ophthalmology Specialties

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review

By MedXY 08/02/2025

The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials

By MedXY 07/31/2025

Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.

Clinical Updates news Ophthalmology Otorhinolaryngology Specialties

GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis

By MedXY 07/30/2025

GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.